About US
Contact us
-
Roche's Tecentriq-Avastin lung cancer combo gets a lift from England's cost watchdogsRoche has some hard-earned knowledge about working with England’s cost watchdogs, especially where its cancer drugs are concerned. And it put that know-how to use to score backing for Tecentriq in lu2019/4/30
-
GSK's Shingrix skyrockets toward the £1B mark as HIV drugs falterGlaxoSmithKline’s shingles vaccine Shingrix is growing insanely fast. So fast, in fact, it's on track to surpass £1 billion in sales for its second full year on the market. But another pillar of the2019/4/30
-
Eli Lilly aims to keep current Lartruvo patients as drug exits world stageEli Lilly'shigh hopes for Lartruvo hit the skids in January when the soft tissue sarcoma therapy flunked a phase 3 trial. Now that the failed drug is movingoff the market, Lilly's trying to keep curr2019/4/29
-
Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begunAbbVie's Humira just posted its first-ever drop in worldwide sales—and with biosimilars on the march in Europe, it's not likely to be the last. Make no mistake; AbbVie is still making a fortune off t2019/4/29
-
As Roundup suits pile on, Bayer's drugs deliver a surprisingly good showIt’s no surprise that blood thinner Xarelto and vision drug Eylea drove Bayer’s pharma growth again this quarter—they have beenfor a long time. But cancer drugs Nexavar and Stivarga and hemophilia th2019/4/28
-
Bristol arms itself for kidney-cancer fight as Keytruda threatens Opdivo's shareBristol-Myers Squibb investors have been dreading the arrival of Merck’s Keytruda in kidney cancer, one of Opdivo’s key growth areas. Bristol’s execs? Not so much. The company has been preparing for2019/4/28
-
Feds say Astellas, Amgen will fork over $125M to settle charity kickback probesThe Justice Department has swept pharma companies large and small into an investigation examining the ties between drugmakers and patient charities, and now two more—Astellas and Amgen—haveinkedset2019/4/26
-
Good news for AZ's 'next phase of growth': Its cancer drugs have shifted into high gearFor the first time, AstraZeneca's top-selling medicine isn't a stomach drug or a respiratory inhaler or any other primary care med. It's a cancer drug.That would be Tagrisso, the EGFR inhibitor for l2019/4/26
-
FiercePharmaAsia—Lilly China asset sale; Daiichi's bispecific I-O deal; Torrent 1M-bottle sartan recallJoining its Big Pharma peers in selling legacy brands in China to focus on newer, innovative therapies, Eli Lilly decided to cast off two decades-old antibiotic brands in the country. With a renewed2019/4/25
-
BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flopBristol-Myers Squibb already has one Opdivo approval in previously treated head and neck cancer, but it won’t make that two. The company, which was testing its immuno-oncology star alongside Yervoy i2019/4/25